Sustained gut dysbiosis and intestinal inflammation show correlation with weight gain in person with chronic HIV infection on antiretroviral therapy
Person with human immunodeficiency virus type-1 (PWH) are prone to chronic inflammation due to residual viral production, even with antiretroviral therapy (ART), which increases the risk of age-related diseases. There is also limited information on changes in the intestinal environment of PWH during...
Saved in:
| Published in | BMC microbiology Vol. 24; no. 1; pp. 274 - 13 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
24.07.2024
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Person with human immunodeficiency virus type-1 (PWH) are prone to chronic inflammation due to residual viral production, even with antiretroviral therapy (ART), which increases the risk of age-related diseases. There is also limited information on changes in the intestinal environment of PWH during ART. In this longitudinal study, we investigated changes in the gut microbiota, persistence of chronic inflammation, interactions between the gut environment and inflammation, and metabolic changes in PWH using long-term ART.
We analyzed changes in clinical parameters and gut microbiota in 46 PWH over a mean period of 4 years to understand the influence of gut dysbiosis on inflammation. Overall, changes in the gut microbiota included a decrease in some bacteria, mainly involved in short-chain fatty acid (SCFA) production, and an increase in certain opportunistic bacteria. Throughout the study period, an increase in bacterial-specific metabolic activity was observed in the intestinal environment. Continued decline in certain bacteria belonging to the Clostridia class and metabolic changes in gut bacteria involved in glucose metabolism. Additionally, patients with a low abundance of Parabacteroides exhibited low bacterial alpha diversity and a significant increase in body mass index (BMI) during the study period. Monocyte chemoattractant protein 1, a marker of macrophage activation in the plasma, continued to increase from baseline (first stool collection timepoint) to follow-up (second stool collection timepoint), demonstrating a mild correlation with BMI. Elevated BMI was mild to moderately correlated with elevated levels of plasma interleukin 16 and chemokine ligand 13, both of which may play a role in intestinal inflammation and bacterial translocation within the gut microbiota. The rate of BMI increase correlated with the rate of decrease in certain SCFA-producing bacteria, such as Anaerostipes and Coprococcus 3.
Our data suggest that despite effective ART, PWH with chronic inflammation exhibit persistent dysbiosis associated with gut inflammation, resulting in a transition to an intestinal environment with metabolic consequences. Moreover, the loss of certain bacteria such as Parabacteroides in PWH correlates with weight gain and may contribute to the development of metabolic diseases. |
|---|---|
| AbstractList | Abstract Background Person with human immunodeficiency virus type-1 (PWH) are prone to chronic inflammation due to residual viral production, even with antiretroviral therapy (ART), which increases the risk of age-related diseases. There is also limited information on changes in the intestinal environment of PWH during ART. In this longitudinal study, we investigated changes in the gut microbiota, persistence of chronic inflammation, interactions between the gut environment and inflammation, and metabolic changes in PWH using long-term ART. Results We analyzed changes in clinical parameters and gut microbiota in 46 PWH over a mean period of 4 years to understand the influence of gut dysbiosis on inflammation. Overall, changes in the gut microbiota included a decrease in some bacteria, mainly involved in short-chain fatty acid (SCFA) production, and an increase in certain opportunistic bacteria. Throughout the study period, an increase in bacterial-specific metabolic activity was observed in the intestinal environment. Continued decline in certain bacteria belonging to the Clostridia class and metabolic changes in gut bacteria involved in glucose metabolism. Additionally, patients with a low abundance of Parabacteroides exhibited low bacterial alpha diversity and a significant increase in body mass index (BMI) during the study period. Monocyte chemoattractant protein 1, a marker of macrophage activation in the plasma, continued to increase from baseline (first stool collection timepoint) to follow-up (second stool collection timepoint), demonstrating a mild correlation with BMI. Elevated BMI was mild to moderately correlated with elevated levels of plasma interleukin 16 and chemokine ligand 13, both of which may play a role in intestinal inflammation and bacterial translocation within the gut microbiota. The rate of BMI increase correlated with the rate of decrease in certain SCFA-producing bacteria, such as Anaerostipes and Coprococcus 3. Conclusion Our data suggest that despite effective ART, PWH with chronic inflammation exhibit persistent dysbiosis associated with gut inflammation, resulting in a transition to an intestinal environment with metabolic consequences. Moreover, the loss of certain bacteria such as Parabacteroides in PWH correlates with weight gain and may contribute to the development of metabolic diseases. Background Person with human immunodeficiency virus type-1 (PWH) are prone to chronic inflammation due to residual viral production, even with antiretroviral therapy (ART), which increases the risk of age-related diseases. There is also limited information on changes in the intestinal environment of PWH during ART. In this longitudinal study, we investigated changes in the gut microbiota, persistence of chronic inflammation, interactions between the gut environment and inflammation, and metabolic changes in PWH using long-term ART. Results We analyzed changes in clinical parameters and gut microbiota in 46 PWH over a mean period of 4 years to understand the influence of gut dysbiosis on inflammation. Overall, changes in the gut microbiota included a decrease in some bacteria, mainly involved in short-chain fatty acid (SCFA) production, and an increase in certain opportunistic bacteria. Throughout the study period, an increase in bacterial-specific metabolic activity was observed in the intestinal environment. Continued decline in certain bacteria belonging to the Clostridia class and metabolic changes in gut bacteria involved in glucose metabolism. Additionally, patients with a low abundance of Parabacteroides exhibited low bacterial alpha diversity and a significant increase in body mass index (BMI) during the study period. Monocyte chemoattractant protein 1, a marker of macrophage activation in the plasma, continued to increase from baseline (first stool collection timepoint) to follow-up (second stool collection timepoint), demonstrating a mild correlation with BMI. Elevated BMI was mild to moderately correlated with elevated levels of plasma interleukin 16 and chemokine ligand 13, both of which may play a role in intestinal inflammation and bacterial translocation within the gut microbiota. The rate of BMI increase correlated with the rate of decrease in certain SCFA-producing bacteria, such as Anaerostipes and Coprococcus 3. Conclusion Our data suggest that despite effective ART, PWH with chronic inflammation exhibit persistent dysbiosis associated with gut inflammation, resulting in a transition to an intestinal environment with metabolic consequences. Moreover, the loss of certain bacteria such as Parabacteroides in PWH correlates with weight gain and may contribute to the development of metabolic diseases. Keywords: HIV, Microbiota, Chronic inflammation Person with human immunodeficiency virus type-1 (PWH) are prone to chronic inflammation due to residual viral production, even with antiretroviral therapy (ART), which increases the risk of age-related diseases. There is also limited information on changes in the intestinal environment of PWH during ART. In this longitudinal study, we investigated changes in the gut microbiota, persistence of chronic inflammation, interactions between the gut environment and inflammation, and metabolic changes in PWH using long-term ART.BACKGROUNDPerson with human immunodeficiency virus type-1 (PWH) are prone to chronic inflammation due to residual viral production, even with antiretroviral therapy (ART), which increases the risk of age-related diseases. There is also limited information on changes in the intestinal environment of PWH during ART. In this longitudinal study, we investigated changes in the gut microbiota, persistence of chronic inflammation, interactions between the gut environment and inflammation, and metabolic changes in PWH using long-term ART.We analyzed changes in clinical parameters and gut microbiota in 46 PWH over a mean period of 4 years to understand the influence of gut dysbiosis on inflammation. Overall, changes in the gut microbiota included a decrease in some bacteria, mainly involved in short-chain fatty acid (SCFA) production, and an increase in certain opportunistic bacteria. Throughout the study period, an increase in bacterial-specific metabolic activity was observed in the intestinal environment. Continued decline in certain bacteria belonging to the Clostridia class and metabolic changes in gut bacteria involved in glucose metabolism. Additionally, patients with a low abundance of Parabacteroides exhibited low bacterial alpha diversity and a significant increase in body mass index (BMI) during the study period. Monocyte chemoattractant protein 1, a marker of macrophage activation in the plasma, continued to increase from baseline (first stool collection timepoint) to follow-up (second stool collection timepoint), demonstrating a mild correlation with BMI. Elevated BMI was mild to moderately correlated with elevated levels of plasma interleukin 16 and chemokine ligand 13, both of which may play a role in intestinal inflammation and bacterial translocation within the gut microbiota. The rate of BMI increase correlated with the rate of decrease in certain SCFA-producing bacteria, such as Anaerostipes and Coprococcus 3.RESULTSWe analyzed changes in clinical parameters and gut microbiota in 46 PWH over a mean period of 4 years to understand the influence of gut dysbiosis on inflammation. Overall, changes in the gut microbiota included a decrease in some bacteria, mainly involved in short-chain fatty acid (SCFA) production, and an increase in certain opportunistic bacteria. Throughout the study period, an increase in bacterial-specific metabolic activity was observed in the intestinal environment. Continued decline in certain bacteria belonging to the Clostridia class and metabolic changes in gut bacteria involved in glucose metabolism. Additionally, patients with a low abundance of Parabacteroides exhibited low bacterial alpha diversity and a significant increase in body mass index (BMI) during the study period. Monocyte chemoattractant protein 1, a marker of macrophage activation in the plasma, continued to increase from baseline (first stool collection timepoint) to follow-up (second stool collection timepoint), demonstrating a mild correlation with BMI. Elevated BMI was mild to moderately correlated with elevated levels of plasma interleukin 16 and chemokine ligand 13, both of which may play a role in intestinal inflammation and bacterial translocation within the gut microbiota. The rate of BMI increase correlated with the rate of decrease in certain SCFA-producing bacteria, such as Anaerostipes and Coprococcus 3.Our data suggest that despite effective ART, PWH with chronic inflammation exhibit persistent dysbiosis associated with gut inflammation, resulting in a transition to an intestinal environment with metabolic consequences. Moreover, the loss of certain bacteria such as Parabacteroides in PWH correlates with weight gain and may contribute to the development of metabolic diseases.CONCLUSIONOur data suggest that despite effective ART, PWH with chronic inflammation exhibit persistent dysbiosis associated with gut inflammation, resulting in a transition to an intestinal environment with metabolic consequences. Moreover, the loss of certain bacteria such as Parabacteroides in PWH correlates with weight gain and may contribute to the development of metabolic diseases. Person with human immunodeficiency virus type-1 (PWH) are prone to chronic inflammation due to residual viral production, even with antiretroviral therapy (ART), which increases the risk of age-related diseases. There is also limited information on changes in the intestinal environment of PWH during ART. In this longitudinal study, we investigated changes in the gut microbiota, persistence of chronic inflammation, interactions between the gut environment and inflammation, and metabolic changes in PWH using long-term ART. We analyzed changes in clinical parameters and gut microbiota in 46 PWH over a mean period of 4 years to understand the influence of gut dysbiosis on inflammation. Overall, changes in the gut microbiota included a decrease in some bacteria, mainly involved in short-chain fatty acid (SCFA) production, and an increase in certain opportunistic bacteria. Throughout the study period, an increase in bacterial-specific metabolic activity was observed in the intestinal environment. Continued decline in certain bacteria belonging to the Clostridia class and metabolic changes in gut bacteria involved in glucose metabolism. Additionally, patients with a low abundance of Parabacteroides exhibited low bacterial alpha diversity and a significant increase in body mass index (BMI) during the study period. Monocyte chemoattractant protein 1, a marker of macrophage activation in the plasma, continued to increase from baseline (first stool collection timepoint) to follow-up (second stool collection timepoint), demonstrating a mild correlation with BMI. Elevated BMI was mild to moderately correlated with elevated levels of plasma interleukin 16 and chemokine ligand 13, both of which may play a role in intestinal inflammation and bacterial translocation within the gut microbiota. The rate of BMI increase correlated with the rate of decrease in certain SCFA-producing bacteria, such as Anaerostipes and Coprococcus 3. Our data suggest that despite effective ART, PWH with chronic inflammation exhibit persistent dysbiosis associated with gut inflammation, resulting in a transition to an intestinal environment with metabolic consequences. Moreover, the loss of certain bacteria such as Parabacteroides in PWH correlates with weight gain and may contribute to the development of metabolic diseases. Person with human immunodeficiency virus type-1 (PWH) are prone to chronic inflammation due to residual viral production, even with antiretroviral therapy (ART), which increases the risk of age-related diseases. There is also limited information on changes in the intestinal environment of PWH during ART. In this longitudinal study, we investigated changes in the gut microbiota, persistence of chronic inflammation, interactions between the gut environment and inflammation, and metabolic changes in PWH using long-term ART. We analyzed changes in clinical parameters and gut microbiota in 46 PWH over a mean period of 4 years to understand the influence of gut dysbiosis on inflammation. Overall, changes in the gut microbiota included a decrease in some bacteria, mainly involved in short-chain fatty acid (SCFA) production, and an increase in certain opportunistic bacteria. Throughout the study period, an increase in bacterial-specific metabolic activity was observed in the intestinal environment. Continued decline in certain bacteria belonging to the Clostridia class and metabolic changes in gut bacteria involved in glucose metabolism. Additionally, patients with a low abundance of Parabacteroides exhibited low bacterial alpha diversity and a significant increase in body mass index (BMI) during the study period. Monocyte chemoattractant protein 1, a marker of macrophage activation in the plasma, continued to increase from baseline (first stool collection timepoint) to follow-up (second stool collection timepoint), demonstrating a mild correlation with BMI. Elevated BMI was mild to moderately correlated with elevated levels of plasma interleukin 16 and chemokine ligand 13, both of which may play a role in intestinal inflammation and bacterial translocation within the gut microbiota. The rate of BMI increase correlated with the rate of decrease in certain SCFA-producing bacteria, such as Anaerostipes and Coprococcus 3. Our data suggest that despite effective ART, PWH with chronic inflammation exhibit persistent dysbiosis associated with gut inflammation, resulting in a transition to an intestinal environment with metabolic consequences. Moreover, the loss of certain bacteria such as Parabacteroides in PWH correlates with weight gain and may contribute to the development of metabolic diseases. BackgroundPerson with human immunodeficiency virus type-1 (PWH) are prone to chronic inflammation due to residual viral production, even with antiretroviral therapy (ART), which increases the risk of age-related diseases. There is also limited information on changes in the intestinal environment of PWH during ART. In this longitudinal study, we investigated changes in the gut microbiota, persistence of chronic inflammation, interactions between the gut environment and inflammation, and metabolic changes in PWH using long-term ART.ResultsWe analyzed changes in clinical parameters and gut microbiota in 46 PWH over a mean period of 4 years to understand the influence of gut dysbiosis on inflammation. Overall, changes in the gut microbiota included a decrease in some bacteria, mainly involved in short-chain fatty acid (SCFA) production, and an increase in certain opportunistic bacteria. Throughout the study period, an increase in bacterial-specific metabolic activity was observed in the intestinal environment. Continued decline in certain bacteria belonging to the Clostridia class and metabolic changes in gut bacteria involved in glucose metabolism. Additionally, patients with a low abundance of Parabacteroides exhibited low bacterial alpha diversity and a significant increase in body mass index (BMI) during the study period. Monocyte chemoattractant protein 1, a marker of macrophage activation in the plasma, continued to increase from baseline (first stool collection timepoint) to follow-up (second stool collection timepoint), demonstrating a mild correlation with BMI. Elevated BMI was mild to moderately correlated with elevated levels of plasma interleukin 16 and chemokine ligand 13, both of which may play a role in intestinal inflammation and bacterial translocation within the gut microbiota. The rate of BMI increase correlated with the rate of decrease in certain SCFA-producing bacteria, such as Anaerostipes and Coprococcus 3.ConclusionOur data suggest that despite effective ART, PWH with chronic inflammation exhibit persistent dysbiosis associated with gut inflammation, resulting in a transition to an intestinal environment with metabolic consequences. Moreover, the loss of certain bacteria such as Parabacteroides in PWH correlates with weight gain and may contribute to the development of metabolic diseases. |
| ArticleNumber | 274 |
| Audience | Academic |
| Author | Ishizaka, Aya Koga, Michiko Suzuki, Yutaka Yotsuyanagi, Hiroshi Matano, Tetsuro Mizutani, Taketoshi |
| Author_xml | – sequence: 1 givenname: Aya surname: Ishizaka fullname: Ishizaka, Aya – sequence: 2 givenname: Michiko surname: Koga fullname: Koga, Michiko – sequence: 3 givenname: Taketoshi surname: Mizutani fullname: Mizutani, Taketoshi – sequence: 4 givenname: Yutaka surname: Suzuki fullname: Suzuki, Yutaka – sequence: 5 givenname: Tetsuro surname: Matano fullname: Matano, Tetsuro – sequence: 6 givenname: Hiroshi surname: Yotsuyanagi fullname: Yotsuyanagi, Hiroshi |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39044127$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1u1DAUhSNURH_gBVigSGzKIsXXdvyzQlUFdKRKSBTYWh7HSVxl4sF2Osx78MB4ZtrSqRCKpVjX3zm2r89xcTD60RbFa0BnAIK9j4AFYxXCtEKEEqjQs-IIKIcKg0AHj-aHxXGMNwgBF4S_KA6JRJQC5kfF7-spJu1G25TdlMpmHefORxdLPTalG5ONyY16yNN20IuFTs6PZez9qjQ-BDvsCiuX-nJlXdensstuGS-XNsT7JdMHPzpTXs5-bJys2ary0GNywabgb13Iu6TeBr1cvyyet3qI9tXd_6T4_unjt4vL6urL59nF-VVlailSBaQ1lmLGOMF8LjDFhCOshSANl5pDS1hrQFtTM0EsBiklx5IDq6FtTcvISTHb-TZe36hlcAsd1sprp7YFHzqlQ3JmsAo3di50I6FhkjJiBFAswbaCIA6C6uz1Yee1nOYL2xg7pnyjPdP9ldH1qvO3CgAzLmqUHU7vHIL_OeXGq4WLxg6DHq2foiJIUIQllTijb5-gN34K-Z02lAQscc3kX6rT-Qa57z5vbDam6lzk1ABIWmfq7B9U_hq7cCYnrnW5vid4tyfITLK_UqenGNXs-us---ZxVx7acR_ADOAdYIKPMdj2AQGkNilXu5SrbKm2KVebToknIuPSNon56G74n_QPC3wAjA |
| CitedBy_id | crossref_primary_10_3390_microorganisms12112221 crossref_primary_10_3390_life14111367 |
| Cites_doi | 10.1038/s41598-020-76474-8 10.1186/s12915-019-0699-4 10.1186/s12866-024-03351-z 10.3389/fcimb.2020.00434 10.1080/19490976.2019.1700756 10.3389/fimmu.2019.00289 10.1093/infdis/jiv501 10.1371/journal.ppat.1011219 10.3390/v13102101 10.1038/s41587-020-0548-6 10.1128/Spectrum.00708-21 10.3389/fimmu.2021.639291 10.1136/bmj.310.6973.165 10.1097/COH.0000000000000230 10.1016/j.cell.2021.05.023 10.1128/spectrum.01064-23 10.1016/j.ebiom.2022.104182 10.3390/nu12041107 10.1038/s41586-021-03832-5 10.1038/s41467-023-44566-4 10.1038/s41467-022-32015-7 10.1186/s40168-021-01168-w 10.1038/mi.2013.116 10.1089/jir.2008.0027 10.1073/pnas.1917876117 10.1093/nar/28.1.27 10.1074/jbc.M601284200 10.1038/s41587-019-0209-9 10.1038/s41467-020-16222-8 10.1194/jlr.M041392 10.1038/s41467-022-29589-7 10.1186/s12866-023-03157-5 10.1371/journal.ppat.1007611 10.1016/j.cell.2014.09.053 10.3748/wjg.v16.i42.5272 10.1016/j.ebiom.2018.03.024 10.3389/fmicb.2024.1359402 10.1172/jci.insight.146162 10.1038/nrmicro2848 10.1093/infdis/jiaa379 10.1371/journal.pcbi.1009442 10.3389/fimmu.2019.00463 10.1038/ijo.2011.168 10.1016/S0140-6736(13)61809-7 10.1016/j.celrep.2018.12.028 10.1038/sj.ijo.0803259 10.1038/s41522-019-0101-x 10.3390/v14050950 10.1007/s10753-020-01253-6 10.1016/j.chom.2023.08.006 10.1136/gut.48.3.326 10.1161/CIRCRESAHA.115.306807 10.1038/nmeth.3869 10.1111/imr.12065 10.1128/JVI.03158-15 10.1128/spectrum.01689-21 10.1172/JCI26498 |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 2024 |
| Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 2024 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7QL 7T7 7U9 7X7 7XB 88E 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU COVID DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7N M7P P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12866-024-03431-0 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science (UHCL Subscription) ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Industrial and Applied Microbiology Abstracts (Microbiology A) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Database ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Coronavirus Research Database ProQuest Central Engineering Research Database Health Research Premium Collection (UHCL Subscription) Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection (UHCL Subscription) ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection Environmental Sciences and Pollution Management ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1471-2180 |
| EndPage | 13 |
| ExternalDocumentID | oai_doaj_org_article_2deb8ad91d69463c814291ef8307184a PMC11267850 A802411945 39044127 10_1186_s12866_024_03431_0 |
| Genre | Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GrantInformation_xml | – fundername: Japan Agency for Medical Research and Development grantid: 223fa627001h0001 – fundername: Japan Society for the Promotion of Science grantid: 21K11592 – fundername: Japan Society for the Promotion of Science grantid: 22K20926 – fundername: Japan Science and Technology Agency grantid: JPMJMS2025 – fundername: Japan Agency for Medical Research and Development grantid: JP223fa627001 – fundername: Japan Society for the Promotion of Science grantid: 21K07314 – fundername: Ministry of Health, Labour and Welfare grantid: 21HB2005 |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 7X7 88E 8FE 8FH 8FI 8FJ A8Z AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IGS IHR INH INR ISR ITC KQ8 LK5 LK8 M1P M48 M7P M7R MM. M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB ~02 CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB PMFND 3V. 7QL 7T7 7U9 7XB 8FD 8FK AZQEC C1K COVID DWQXO FR3 GNUQQ H94 K9. M7N P64 PKEHL PQEST PQUKI 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c598t-13fce42667327b82423702a883d79a71f36fc1aec5683e2199972971651ffcf63 |
| IEDL.DBID | M48 |
| ISSN | 1471-2180 |
| IngestDate | Wed Aug 27 01:31:11 EDT 2025 Thu Aug 21 18:33:39 EDT 2025 Thu Jul 10 19:13:08 EDT 2025 Fri Jul 25 19:19:38 EDT 2025 Tue Jun 17 22:07:38 EDT 2025 Tue Jun 10 21:07:46 EDT 2025 Fri Jun 27 05:30:28 EDT 2025 Mon Jul 21 05:33:34 EDT 2025 Tue Jul 01 04:31:46 EDT 2025 Thu Apr 24 23:01:36 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | HIV Chronic inflammation Microbiota |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c598t-13fce42667327b82423702a883d79a71f36fc1aec5683e2199972971651ffcf63 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12866-024-03431-0 |
| PMID | 39044127 |
| PQID | 3091292569 |
| PQPubID | 42585 |
| PageCount | 13 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_2deb8ad91d69463c814291ef8307184a pubmedcentral_primary_oai_pubmedcentral_nih_gov_11267850 proquest_miscellaneous_3084029492 proquest_journals_3091292569 gale_infotracmisc_A802411945 gale_infotracacademiconefile_A802411945 gale_incontextgauss_ISR_A802411945 pubmed_primary_39044127 crossref_primary_10_1186_s12866_024_03431_0 crossref_citationtrail_10_1186_s12866_024_03431_0 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-07-24 |
| PublicationDateYYYYMMDD | 2024-07-24 |
| PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-24 day: 24 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC microbiology |
| PublicationTitleAlternate | BMC Microbiol |
| PublicationYear | 2024 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | JP Derikx (3431_CR26) 2010; 16 OE Asowata (3431_CR10) 2021; 6 3431_CR29 J Fu (3431_CR52) 2015; 117 VRR Mehraj (3431_CR35) 2019; 10 M Rocafort (3431_CR19) 2024; 15 E Scully (3431_CR44) 2016; 213 S Serrano-Villar (3431_CR23) 2021; 223 NR Klatt (3431_CR4) 2013; 254 H Imamichi (3431_CR6) 2020; 117 JL Waters (3431_CR53) 2019; 17 VE Van Doren (3431_CR30) 2023; 19 H Kanda (3431_CR42) 2006; 116 M Kanehisa (3431_CR63) 2000; 28 C Quast (3431_CR58) 2013; 41 GV Fabian Pedregosa (3431_CR59) 2011; 12 3431_CR12 A Ishizaka (3431_CR28) 2021; 9 Y Fu (3431_CR15) 2024; 24 SM Dillon (3431_CR11) 2014; 7 S Li (3431_CR24) 2023; 11 N Kamei (3431_CR41) 2006; 281 K Nganou-Makamdop (3431_CR20) 2024; 9 N Rhoades (3431_CR27) 2019; 10 A Ishizaka (3431_CR31) 2024; 24 H Mallick (3431_CR60) 2021; 17 GM Douglas (3431_CR62) 2020; 38 H Streeck (3431_CR7) 2022; 83 YH Chang (3431_CR38) 2012; 36 JK Goodrich (3431_CR54) 2014; 159 K Hosomi (3431_CR45) 2022; 13 I Vujkovic-Cvijin (3431_CR14) 2020; 11 DC Lloyd (3431_CR48) 1995; 310 SL Coleman (3431_CR17) 2020; 11 Y Chen (3431_CR18) 2021; 9 K Wang (3431_CR50) 2019; 26 CH Tsao (3431_CR39) 2014; 55 CS Kim (3431_CR40) 2006; 30 V Mehraj (3431_CR37) 2019; 10 M Dube (3431_CR3) 2023; 31 SL Deshmane (3431_CR43) 2009; 29 G Ancona (3431_CR21) 2021; 12 SX Li (3431_CR13) 2019; 15 MH Kim (3431_CR61) 2020; 10 D Seegert (3431_CR34) 2001; 48 LR Runtuwene (3431_CR25) 2024; 15 A Ishizaka (3431_CR5) 2016; 90 Y Sato (3431_CR51) 2021; 599 Y Abreu (3431_CR47) 2021; 86 N Ozato (3431_CR46) 2019; 5 K Nganou-Makamdop (3431_CR22) 2021; 184 E Bolyen (3431_CR56) 2019; 37 M Massanella (3431_CR2) 2016; 11 J Zhou (3431_CR16) 2020; 10 T Mizutani (3431_CR55) 2022; 10 W Chen (3431_CR36) 2020; 43 D Khanna (3431_CR33) 2022; 14 SG Deeks (3431_CR1) 2013; 382 NG Sandler (3431_CR8) 2012; 10 M Li (3431_CR49) 2022; 13 3431_CR32 T Mizutani (3431_CR9) 2022; 14 BJ Callahan (3431_CR57) 2016; 13 |
| References_xml | – volume: 10 start-page: 19417 issue: 1 year: 2020 ident: 3431_CR61 publication-title: Sci Rep doi: 10.1038/s41598-020-76474-8 – volume: 17 start-page: 83 issue: 1 year: 2019 ident: 3431_CR53 publication-title: BMC Biol doi: 10.1186/s12915-019-0699-4 – volume: 24 start-page: 192 issue: 1 year: 2024 ident: 3431_CR15 publication-title: BMC Microbiol doi: 10.1186/s12866-024-03351-z – volume: 10 start-page: 434 year: 2020 ident: 3431_CR16 publication-title: Front Cell Infect Microbiol doi: 10.3389/fcimb.2020.00434 – volume: 11 start-page: 610 issue: 3 year: 2020 ident: 3431_CR17 publication-title: Gut Microbes doi: 10.1080/19490976.2019.1700756 – volume: 10 start-page: 289 year: 2019 ident: 3431_CR35 publication-title: Front Immunol doi: 10.3389/fimmu.2019.00289 – volume: 213 start-page: 771 issue: 5 year: 2016 ident: 3431_CR44 publication-title: J Infect Dis doi: 10.1093/infdis/jiv501 – volume: 86 start-page: 287 issue: 3 year: 2021 ident: 3431_CR47 publication-title: Rev Gastroenterol Mex (Engl Ed) – volume: 19 start-page: e1011219 issue: 5 year: 2023 ident: 3431_CR30 publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1011219 – ident: 3431_CR29 doi: 10.3390/v13102101 – volume: 38 start-page: 685 issue: 6 year: 2020 ident: 3431_CR62 publication-title: Nat Biotechnol doi: 10.1038/s41587-020-0548-6 – volume: 9 start-page: e0070821 issue: 1 year: 2021 ident: 3431_CR28 publication-title: Microbiol Spectr doi: 10.1128/Spectrum.00708-21 – volume: 12 start-page: 639291 year: 2021 ident: 3431_CR21 publication-title: Front Immunol doi: 10.3389/fimmu.2021.639291 – volume: 310 start-page: 165 issue: 6973 year: 1995 ident: 3431_CR48 publication-title: BMJ doi: 10.1136/bmj.310.6973.165 – volume: 11 start-page: 234 issue: 2 year: 2016 ident: 3431_CR2 publication-title: Curr Opin HIV AIDS doi: 10.1097/COH.0000000000000230 – volume: 184 start-page: 3899 issue: 15 year: 2021 ident: 3431_CR22 publication-title: Cell doi: 10.1016/j.cell.2021.05.023 – volume: 11 start-page: e0106423 issue: 6 year: 2023 ident: 3431_CR24 publication-title: Microbiol Spectr doi: 10.1128/spectrum.01064-23 – volume: 83 start-page: 104182 year: 2022 ident: 3431_CR7 publication-title: EBioMedicine doi: 10.1016/j.ebiom.2022.104182 – ident: 3431_CR32 doi: 10.3390/nu12041107 – volume: 599 start-page: 458 issue: 7885 year: 2021 ident: 3431_CR51 publication-title: Nature doi: 10.1038/s41586-021-03832-5 – volume: 15 start-page: 1055 issue: 1 year: 2024 ident: 3431_CR19 publication-title: Nat Commun doi: 10.1038/s41467-023-44566-4 – volume: 13 start-page: 4477 issue: 1 year: 2022 ident: 3431_CR45 publication-title: Nat Commun doi: 10.1038/s41467-022-32015-7 – volume: 9 start-page: 237 issue: 1 year: 2021 ident: 3431_CR18 publication-title: Microbiome doi: 10.1186/s40168-021-01168-w – volume: 14 start-page: e22711 issue: 2 year: 2022 ident: 3431_CR33 publication-title: Cureus – volume: 7 start-page: 983 issue: 4 year: 2014 ident: 3431_CR11 publication-title: Mucosal Immunol doi: 10.1038/mi.2013.116 – volume: 29 start-page: 313 issue: 6 year: 2009 ident: 3431_CR43 publication-title: J Interferon Cytokine Res doi: 10.1089/jir.2008.0027 – volume: 12 start-page: 2825 year: 2011 ident: 3431_CR59 publication-title: J Mach Learn Res – volume: 117 start-page: 3704 issue: 7 year: 2020 ident: 3431_CR6 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1917876117 – volume: 28 start-page: 27 issue: 1 year: 2000 ident: 3431_CR63 publication-title: Nucleic Acids Res doi: 10.1093/nar/28.1.27 – volume: 281 start-page: 26602 issue: 36 year: 2006 ident: 3431_CR41 publication-title: J Biol Chem doi: 10.1074/jbc.M601284200 – volume: 37 start-page: 852 issue: 8 year: 2019 ident: 3431_CR56 publication-title: Nat Biotechnol doi: 10.1038/s41587-019-0209-9 – volume: 11 start-page: 2448 issue: 1 year: 2020 ident: 3431_CR14 publication-title: Nat Commun doi: 10.1038/s41467-020-16222-8 – volume: 55 start-page: 385 issue: 3 year: 2014 ident: 3431_CR39 publication-title: J Lipid Res doi: 10.1194/jlr.M041392 – volume: 13 start-page: 2060 issue: 1 year: 2022 ident: 3431_CR49 publication-title: Nat Commun doi: 10.1038/s41467-022-29589-7 – volume: 24 start-page: 6 issue: 1 year: 2024 ident: 3431_CR31 publication-title: BMC Microbiol doi: 10.1186/s12866-023-03157-5 – volume: 15 start-page: e1007611 issue: 4 year: 2019 ident: 3431_CR13 publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1007611 – volume: 159 start-page: 789 issue: 4 year: 2014 ident: 3431_CR54 publication-title: Cell doi: 10.1016/j.cell.2014.09.053 – volume: 16 start-page: 5272 issue: 42 year: 2010 ident: 3431_CR26 publication-title: World J Gastroenterol doi: 10.3748/wjg.v16.i42.5272 – ident: 3431_CR12 doi: 10.1016/j.ebiom.2018.03.024 – volume: 15 start-page: 1359402 year: 2024 ident: 3431_CR25 publication-title: Front Microbiol doi: 10.3389/fmicb.2024.1359402 – volume: 6 start-page: e146162 issue: 22 year: 2021 ident: 3431_CR10 publication-title: JCI Insight doi: 10.1172/jci.insight.146162 – volume: 10 start-page: 655 issue: 9 year: 2012 ident: 3431_CR8 publication-title: Nat Rev Microbiol doi: 10.1038/nrmicro2848 – volume: 223 start-page: 471 issue: 3 year: 2021 ident: 3431_CR23 publication-title: J Infect Dis doi: 10.1093/infdis/jiaa379 – volume: 17 start-page: e1009442 issue: 11 year: 2021 ident: 3431_CR60 publication-title: PLoS Comput Biol doi: 10.1371/journal.pcbi.1009442 – volume: 10 start-page: 463 year: 2019 ident: 3431_CR27 publication-title: Front Immunol doi: 10.3389/fimmu.2019.00463 – volume: 36 start-page: 993 issue: 7 year: 2012 ident: 3431_CR38 publication-title: Int J Obes (Lond) doi: 10.1038/ijo.2011.168 – volume: 382 start-page: 1525 issue: 9903 year: 2013 ident: 3431_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(13)61809-7 – volume: 26 start-page: 222 issue: 1 year: 2019 ident: 3431_CR50 publication-title: Cell Rep doi: 10.1016/j.celrep.2018.12.028 – volume: 30 start-page: 1347 issue: 9 year: 2006 ident: 3431_CR40 publication-title: Int J Obes (Lond) doi: 10.1038/sj.ijo.0803259 – volume: 5 start-page: 28 issue: 1 year: 2019 ident: 3431_CR46 publication-title: NPJ Biofilms Microbiomes doi: 10.1038/s41522-019-0101-x – volume: 14 start-page: 950 issue: 5 year: 2022 ident: 3431_CR9 publication-title: Viruses doi: 10.3390/v14050950 – volume: 9 start-page: 168 issue: 1 year: 2024 ident: 3431_CR20 publication-title: Pathog Immun – volume: 43 start-page: 1789 issue: 5 year: 2020 ident: 3431_CR36 publication-title: Inflammation doi: 10.1007/s10753-020-01253-6 – volume: 31 start-page: 1507 issue: 9 year: 2023 ident: 3431_CR3 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2023.08.006 – volume: 48 start-page: 326 issue: 3 year: 2001 ident: 3431_CR34 publication-title: Gut doi: 10.1136/gut.48.3.326 – volume: 10 start-page: 289 year: 2019 ident: 3431_CR37 publication-title: Front Immunol doi: 10.3389/fimmu.2019.00289 – volume: 41 start-page: D590 issue: Database issue year: 2013 ident: 3431_CR58 publication-title: Nucleic Acids Res – volume: 117 start-page: 817 issue: 9 year: 2015 ident: 3431_CR52 publication-title: Circ Res doi: 10.1161/CIRCRESAHA.115.306807 – volume: 13 start-page: 581 issue: 7 year: 2016 ident: 3431_CR57 publication-title: Nat Methods doi: 10.1038/nmeth.3869 – volume: 254 start-page: 326 issue: 1 year: 2013 ident: 3431_CR4 publication-title: Immunol Rev doi: 10.1111/imr.12065 – volume: 90 start-page: 5665 issue: 12 year: 2016 ident: 3431_CR5 publication-title: J Virol doi: 10.1128/JVI.03158-15 – volume: 10 start-page: e0168921 issue: 2 year: 2022 ident: 3431_CR55 publication-title: Microbiol Spectr doi: 10.1128/spectrum.01689-21 – volume: 116 start-page: 1494 issue: 6 year: 2006 ident: 3431_CR42 publication-title: J Clin Invest doi: 10.1172/JCI26498 |
| SSID | ssj0017837 |
| Score | 2.43452 |
| Snippet | Person with human immunodeficiency virus type-1 (PWH) are prone to chronic inflammation due to residual viral production, even with antiretroviral therapy... Background Person with human immunodeficiency virus type-1 (PWH) are prone to chronic inflammation due to residual viral production, even with antiretroviral... BackgroundPerson with human immunodeficiency virus type-1 (PWH) are prone to chronic inflammation due to residual viral production, even with antiretroviral... Abstract Background Person with human immunodeficiency virus type-1 (PWH) are prone to chronic inflammation due to residual viral production, even with... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 274 |
| SubjectTerms | Adult Age Age related diseases Anti-Retroviral Agents - therapeutic use Antiretroviral agents Antiretroviral drugs Antiretroviral therapy Antiviral agents Bacteria Bacteria - classification Bacteria - isolation & purification Biological diversity Body Mass Index Body size Body weight Care and treatment Cell activation Chemokines Chronic infection Chronic inflammation Composition Correlation Correlation analysis Cytokines Development and progression Digestive system Drug therapy Dysbacteriosis Dysbiosis - microbiology Fatty acids Female Gastrointestinal Microbiome - drug effects Gastrointestinal tract Glucose metabolism Health aspects Highly active antiretroviral therapy HIV HIV (Viruses) HIV infection HIV Infections - complications HIV Infections - drug therapy HIV Infections - microbiology HIV-1 Human immunodeficiency virus Humans Immunology Infections Inflammation Interleukin 16 Interleukins Intestinal microflora Intestine Intestines - microbiology Longitudinal Studies Macrophages Male Metabolic disorders Microbiota Microbiota (Symbiotic organisms) Microorganisms Middle Aged Monocyte chemoattractant protein Monocyte chemoattractant protein 1 Monocytes Parabacteroides Pathogenesis Physiological aspects Prevention Protein turnover Risk factors Sexual orientation Translocation Weight Gain - drug effects |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fi9QwEA5yIPginj-rp0QRfJByTZM2yeMpHnuCPnie3FtI0nRvQdrD7nLs_3F_sDNJu2wR9EXYp810t818ycykM98Q8hYiY6TNKvLgvMyFtDZ3TuncyaYNrQCYODyH_PK1XlyIz5fV5V6rL8wJS_TAaeKOyyY4ZRvNmlqLmnvFYAdloVUATohOomsENm8Kpsb3BxLirqlERtXHA-zCNSbbirzgYDLzYmaGIlv_n3vynlGaJ0zuWaDTB-T-6DrSk3TLh-RO6B6Su6mZ5PYRuT1PtVChocvNmjbbwa36YTVQ2zUUWSFgMeP1AClAQapYpMNVf0M9duhIOXEUz2XpTTwvpUv4NRCn19ErT0M-kenSxdkPOiVydRQ-oCHYPdd4QgH3TlNd1_YxuTj99P3jIh97LuS-0go707c-oNWWvJROobcli9IqxRuprWQtr1vPbPBVrXgokcQA3HMIuirWtr6t-RNy0PVdeEYox8Y-gQdwsYIApDgvGAvSMl8BChjLCJtUYPxISI59MX6aGJio2iS1GVCbiWozRUbe7665TnQcf5X-gJrdSSKVdvwCAGZGgJl_ASwjbxAXBskyOszGWdrNMJiz82_mRMGfMaZFlZF3o1DbwzN4OxY3wEwgv9ZM8mgmCavZz4cn-JlxNxkMB4CXGpxTnZHXu2G8EjPkutBvUAZC9VILXWbkaULr7rm5LsDrLWVG1AzHs4mZj3Srq8g1jhVmUlXF8_8xlS_IvTKuQZmX4ogcrH9twkvw6dbuVVy-vwFcVEi8 priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgCIkXxPcyBjIIiQcULY6T2H5CAzF1SPDAGOqb5Th2Vwkl3dJq6v_BH8xd7JRFSJP6VJ_bJHe-r9z9jpB3EBkjbFaWutqKtBDGpHUtVVqLxjtfgJjUmIf89r2anRdf5-U8Jtz6WFY56sRBUTedxRz5EQfDlisw0Orj6jLFqVH4djWO0LhL7iF0GUq1mO8CLiYg-hobZWR11IMurrDktkgzDoYzzSbGaMDs_18z3zBN07LJG3bo5BF5GB1Iehw4_pjcce0Tcj-MlNw-JX_OQkeUa-his6bNtq-XXb_sqWkbitgQcKRxPwgWyELoW6T9RXdNLc7pCJVxFLOz9HrImtIF_BqQ09Xgm4clGyB16ez0Fx3LuVoKH-AT6NA15ing2mno7to-I-cnX35-nqVx8kJqSyVxPr23Dm234LmoJfpcIsuNlLwRygjmeeUtM86WleQuRygDcNIh9CqZ99ZX_DnZa7vW7RPKcbyP4w4cLVeAvNS2YMwJw2wJssBYQtjIAm0jLDlOx_ith_BEVjqwTQPb9MA2nSXkw27PKoBy3Er9CTm7o0RA7eGL7mqh4_nUeeNqaRrFmkoVFbeSgaFmzkvQgRAEm4S8RbnQCJnRYk3Owmz6Xp-e_dDHEv4MxK8oE_I-EvkO7sGa2OIATwJRtiaUhxNKONN2ujyKn446pdf_TkBC3uyWcSfWybWu2yANBOy5KlSekBdBWnf3zVUGvm8uEiIncjx5MNOVdnkxII5jn5mQZXZw-3W9JA_y4XSJNC8Oyd76auNegc-2rl8PB_MvYUNA3g priority: 102 providerName: ProQuest |
| Title | Sustained gut dysbiosis and intestinal inflammation show correlation with weight gain in person with chronic HIV infection on antiretroviral therapy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39044127 https://www.proquest.com/docview/3091292569 https://www.proquest.com/docview/3084029492 https://pubmed.ncbi.nlm.nih.gov/PMC11267850 https://doaj.org/article/2deb8ad91d69463c814291ef8307184a |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1fb9MwELfGJiReEP8JjMogJB5QII6T2H5AaEWbOqRNqKOo4sVyHKerNCWjaTX6PfjA3DlpWcTEE1LVh_rc1L4735179ztCXkNkjLBZUehyK8JEGBPmuVRhLorSlQmISY73kCen2WiSfJ6m0x2yaXfUbWBzY2iH_aQmi4t3P3-sP4LCf_AKL7P3DZyxGabSJmHEwSCGEMLvgWUS2NHgJPnzr4KAaGxTOHPjvJ5x8hj-f5_U10xVP43yml06ukfudg4lPWgl4D7ZcdUDcrttMbl-SH6dtRVSrqCz1ZIW6yaf1828oaYqKGJFgIrjfFg6yEZbx0ib8_qKWuzb0WbKUbytpVf-FpXO4NuAnF56X70dsi3ELh0df6Ob9K6Kwgv4BmfqEu8t4LfTttpr_YhMjg6_fhqFXSeG0KZKYr_60jq05YLHIpfog4koNlLyQigjWMmz0jLjbJpJ7mKENgCnHUKxlJWlLTP-mOxWdeWeEsqx3Y_jDhwvl4D85DZhzAnDbAqywVhA2IYF2nYw5dgt40L7cEVmumWbBrZpzzYdBeTtds5lC9LxT-ohcnZLiQDb_oN6MdOdvuq4cLk0hWJFppKMW8nAcDNXSjgTISg2AXmFcqERQqPCHJ2ZWTWNPj4b6wMJD2NMJWlA3nREZQ1rsKYreYCdQNStHuV-jxJ03PaHN-KnNyqiObh6sQKXVQXk5XYYZ2LeXOXqFdJAAB-rRMUBedJK63bdXEXgC8ciILInx72N6Y9U83OPQI51Z0Km0bP_sZXPyZ3Y66AI42Sf7C4XK_cCPL1lPiC3xFQMyN7w8PTLeODvSwZepeF9PPz-G9mJVTQ |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEIIXxJ3AAINAPKBosePEzgNC4zK17PLANtQ34zhOVwklZWk19X_wO_iNnBMnZRHS3ib1qT5Ok5zP59ZzIeQ1eMbYNisKXW5lKKQxYZ6rLMxlUbpSAExyjEMeHKajE_F1kkw2yJ--FgbTKnuZ2ArqorYYI9-OQbHxDBR09mH-K8SpUfjvaj9Cw8Niz63OwWVr3o8_A3_fcL775fjTKOymCoQ2yRTOXi-tQ70kYy5zhfaEjLhRKi5kZiQr47S0zDibpCp2HMv0wQAFtyJhZWnLNIbrXiPXQfFG6OzJydrBYxK8vb4wR6XbDcj-FFN8RRjFQB9GA-XXzgj4XxNcUIXDNM0Lem_3DrndGax0xyPsLtlw1T1yw4-wXN0nv498BZYr6HS5oMWqyWd1M2uoqQqKvShAhOB-ADJgz9dJ0ua0PqcW54L4TDyK0WB63kZp6RSuBuR03voCfsn6Fr50NP5O-_SxisIHcAEye4FxEbh36qvJVg_IyZXw5CHZrOrKPSY0xnFCLnZg2DkB-MytYMxJw2wC2GMsIKxngbZdG3ScxvFTt-6QSrVnmwa26ZZtOgrIu_WeuW8Ccin1R-TsmhIbeLdf1GdT3ckDzQuXK1NkrEgzkcZWMTAMmCsVyFxwuk1AXiEuNLboqDAHaGqWTaPHR9_0joIfYywTSUDedkRlDc9gTVdSAW8Cu3oNKLcGlCBD7HC5h5_uZFij_524gLxcL-NOzMurXL1EGiUinomMB-SRR-v6ueMsAluby4CoAY4HL2a4Us1O2w7nWNcmVRI9ufy-XpCbo-ODfb0_Ptx7Sm7x9qTJkIstsrk4W7pnYC8u8uftIaXkx1VLhb--SnuL |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sustained+gut+dysbiosis+and+intestinal+inflammation+show+correlation+with+weight+gain+in+person+with+chronic+HIV+infection+on+antiretroviral+therapy&rft.jtitle=BMC+microbiology&rft.au=Aya+Ishizaka&rft.au=Michiko+Koga&rft.au=Taketoshi+Mizutani&rft.au=Yutaka+Suzuki&rft.date=2024-07-24&rft.pub=BMC&rft.eissn=1471-2180&rft.volume=24&rft.issue=1&rft.spage=1&rft.epage=13&rft_id=info:doi/10.1186%2Fs12866-024-03431-0&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_2deb8ad91d69463c814291ef8307184a |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2180&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2180&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2180&client=summon |